Corporate Banner
Satellite Banner
Scientific Communities
Become a Member | Sign in
Home>News>This Article

Novozymes and Syngenta Enter Global Commercial Agreement

Published: Friday, October 26, 2012
Last Updated: Friday, October 26, 2012
Bookmark and Share
The partners are entering into an exclusive global marketing and distribution agreement on a unique biofungicide used to combat damaging fungal diseases across a range of crops.

Novozymes and Syngenta announced an exclusive global marketing and distribution agreement on the microbial-based biofungicide Taegro®, a natural solution with multiple modes of action used to combat fungal diseases across various crops. The two companies will join forces to bring Novozymes’ Taegro to farmers worldwide through Syngenta’s global organization.

“This collaboration matches Syngenta’s global market strength and leading position within fungicides and integrated solutions with Novozymes’ deep know-how on sustainable, biobased technologies,” says Thomas Videbæk, Executive Vice President of Novozymes. “Using technology developed by Novozymes, Syngenta will provide farmers all over the world with a biological product to help sustainably combat fungal diseases in a powerful manner.”

“We're delighted to enter into another agreement to commercialize a Novozymes technology. Having worldwide commercial rights for Taegro will further strengthen our ability to offer high-performing integrated crop solutions,” comments John Atkin, Chief Operating Officer of Syngenta.

Combatting fungal diseases with sustainable technologies

Taegro offers a biological solution in the form of a microbial-based fungicide, based on the naturally occurring Bacillus subtilis bacterium, which is complementary to existing fungicide technology. It effectively targets fungal diseases such as Rhizoctonia and Fusarium on fruit and vegetables, and its application is expected to be expanded to a wider portfolio of broad-acre crops such as wheat, soy and corn.

Companies to share task of bringing technology to market

Under the terms of the agreement, Novozymes and Syngenta will share the task of bringing Taegro to market. Syngenta will be responsible for sales, marketing and distribution, while Novozymes will be responsible for production and registration. Trials are planned to secure data to continue to build on the current U.S. registration in other regions, following which the two companies aim for a global rollout.

Financial details about the agreement are not being disclosed.

Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,500+ scientific posters on ePosters
  • More Than 5,200+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Novozymes Forms Albumedix
The new stand-alone company Albumedix will continue to develop albumin-based products and technologies for the pharmaceutical industry.
Wednesday, January 20, 2016
Adisseo,Novozymes Enter Partnership in Probiotics for Animals
The companies will develop a product based on naturally occurring microbes that can reduce antibiotic usage in poultry and brings associated health benefits.
Monday, June 01, 2015
Novozymes, Cargill Continue Bio-Acrylic Acid Partnership as BASF Exits
Novozymes and Cargill remain committed to bringing technology to market.
Wednesday, January 28, 2015
Novozymes, Monsanto Showcase Innovations Expected to Increase Farm Sustainability
Companies’ BioAg Alliance working to develop innovations for agriculture to boost productivity.
Thursday, August 28, 2014
Novozymes and Monsanto Partner
Companies establish The BioAg Alliance to discover, develop and sell microbial solutions which enable farmers to increase crop yields with less input.
Tuesday, December 17, 2013
Novozymes and Raízen to Collaborate on Cellulosic Ethanol
Novozymes will supply enzyme technology to Raízen’s first commercial-scale cellulosic ethanol plant in Brazil.
Friday, September 20, 2013
Europe to Invest €3.8 Billion in the Biobased Economy
48 Companies join forces with the European Commission to set up a Public-Private Partnership and accelerate the deployment of biobased products in Europe.
Monday, July 15, 2013
Novozymes Biopharma Helps Innovative Dry Eye Therapy Move into Clinical Trials
A novel ophthalmic solution has recently obtained FDA approval to undergo Phase I/II clinical trials in the United States.
Monday, May 20, 2013
Novozymes' New CEO Takes Office
Peder Holk Nielsen takes over from Steen Riisgaard in a planned transition, vows to bring more innovation to the market faster.
Tuesday, April 02, 2013
Novozymes Acquires Enzyme Business from Iogen Corporation
The acquisition complements Novozymes’ existing business in the pulp & paper, textile, grain-processing and animal feed industries.
Monday, February 04, 2013
Novozymes and Syngenta to partner in delivering JumpStart® — For enhanced phosphate fertility within bioagriculture
The agreement provides an exclusive expansion into new markets for JumpStart, which is a biological that enhances phosphate fertility in agriculture, offering growers an integrated and sustainable seed care solution
Friday, May 11, 2012
Shengquan and Novozymes in partnership to commercialize cellulosic ethanol
The Chinese Shengquan Group will start commercial production of cellulosic ethanol for solvents and biochemicals in June 2012 utilizing enabling technology from Novozymes
Friday, May 11, 2012
Novozymes reaches 2011 financial targets; cautious 2012 outlook
Novozymes, the world leader in bioinnovation and industrial enzymes, today reported satisfactory 2011 results in line with expectations.
Tuesday, January 24, 2012
Novozymes Biopharma to Present Latest Research on Recombinant Human Albumin at AAPS
Recombinant human albumin as a multifunctional excipient for the stabilisation of therapeutic protein formulations. Study results to be presented at the 2011 AAPS National Biotechnology Conference.
Wednesday, March 23, 2011
Novozymes Announces Master File for Recombinant Albumin
The dossier, containing information on the manufacture and safety of albucult, can help support the medical devices and drug formulation applications.
Friday, September 03, 2010
Scientific News
Unravelling the Role of Key Genes and DNA Methylation in Blood Cell Malignancies
Researchers from the University of Nebraska Medical Center have demonstrated the role of Dnmt3a in safeguarding normal haematopoiesis.
Salford Lung Study - The First Real World Clinical Trial
In this podcast, we learn about the Salford Lung Study and its potential to revolutionize the way we assess new drugs and treatments around the world.
Point of Care Diagnostics - A Cautious Revolution
Advances in molecular biology, coupled with the miniaturization and improved sensitivity of assays and devices in general, have enabled a new wave of point-of-care (POC) or “bedside” diagnostics.
Editing Gene Mutations in Anemia
Researchers successfully use a new gene editing strategy to correct mutations that cause a form of anemia.
Genes Help Track Odd Migrations of Zika Mosquitoes
Study shows that mosquitoes carrying Zika virus or Dengue fever a genetically distinct around the world.
Nanomedicine Aims to Improve HIV Drug Therapies
New research aims to improve the administration and availability of drug therapies to HIV patients using nanotechnology.
Tumor Markers Reveal Lethality Of Bladder Cancers
Researchers found that detection of certain tumor cells in early stage cancers helps identify high-risk cancers.
Gene Editing Corrects Sickle Cell Mutation
Researchers demonstrate a potential pathway to developing gene-editing treatments for sickle cell disease.
Driving Mosquito Evolution to Fight Malaria
Researchers propose insect repellent in conjunction with insecticides to extend current insecticide lifetime.
Lab-on-a-Chip to Help Detect Cancer
In this podcast, we speak to Gustavo Stolovitsky to learn about his career and the work he is doing at IBM Research.
Scroll Up
Scroll Down
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
5,200+ scientific videos